Drug Selection News Today

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus substantially reduced RSV lower respiratory tract...

First and only RSV preventive option authorised for use in China AstraZeneca and Sanofis Beyfortus , a long-acting monoclonal...

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program will kick off next week. The statute sets a deadline of September 1, 2023 for the Secretary of Health and Human...

FDA approves Beyfortus™ to protect infants against RSV disease Beyfortus™ is the first monoclonal antibody approved to protect all infants through their first RSV seasonAcross all clinical...

AstraZeneca Nirsevimab unanimously recommended by FDA Advisory Committee

FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants Nirsevimab would be the first immunization specifically designed to protect all... | June 8, 2023

FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants Nirsevimab would be the first immunization specifically designed to protect

FinancialContent fully hosted finance channel

Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab's consistent and high efficacy against infant hospitalizations

  Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s consistent and high efficacy against infant hospitalizations due to RSVData presented at ESPID add to the body of evidence demonstrating nirsevi...